Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab

Abstract Background Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. Understanding how immunotherapies lead to severe COVID-19 is crucial for improving patient outcomes. Methods Human protein microarrays were used to examine the expression of 440 prot...

Full description

Saved in:
Bibliographic Details
Main Authors: Ziping Li, Fujing Zhang, Xianghong Jin, Junling Zhuang
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Translational Medicine
Subjects:
Multiple myeloma
Immune therapy
Bispecific T-cell engagers
Severe COVID-19
Human protein microarray
Online Access:https://doi.org/10.1186/s12967-025-06140-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06140-y

Similar Items